BTK inhibitors

FDA approved stamp regulations yes go

Pharma

AZ nabs Calquence fixed-duration nod to counter BeOne’s CLL push

The fixed-duration approval for Calquence arrives as BeOne continues to widen its lead in the BTK inhibitor space with Brukinsa.

Angus Liu Feb 20, 2026 11:05am

NVS

Novartis jockeys for Rhapsido FDA nod in unclaimed hives subtype

Feb 18, 2026 9:49am

Narasimhan

Novartis CEO eyes 2026 growth despite record patent cliff

Feb 4, 2026 2:30pm

Graham

Roche eyes busy 2026 despite Vabysmo miss, Tecentriq flop

Jan 29, 2026 11:23am

An envelope with rejected mark Vector illustration

Fierce Biotech

FDA shares CRL for Sanofi MS drug mere weeks after rebuff

Jan 6, 2026 4:30am

Lilly

Why Lilly is betting on 2nd-line CLL despite 1st-line wins

Dec 9, 2025 7:30am